Blog

31
Oct

Change in continuity: Professor Alain Beretz appointed as new Ksilink Chairman

Posted by | No Tags | news | Comments Off on Change in continuity: Professor Alain Beretz appointed as new Ksilink Chairman

On September 24th 2019, Ksilink Board of Directors appointed Professor Alain Beretz (on the left) as new Chairman of the Association, replacing Professor André Syrota (on the right) nominated Honorary Chairman. Please click here to download the press release in English. Please click here to download the press release in French.

Read More
02
Sep

Job posting

Posted by | No Tags | Uncategorized | Comments Off on Job posting

A Pluripotent Stem Cell Biology Research Technician position is available at Ksilink. For more information, please click here.

Read More
24
Apr

New publication in SLAS Discovery

Posted by | No Tags | news | Comments Off on New publication in SLAS Discovery

Dr YongJun Kwon, Ksilink Head of Early Discovery and Technology Development, together with Dr Il Doh from Medical & Bio Device (MBD) Co., Ltd publish a paper entitled “Drug Efficacy Comparison of 3D Forming and Preforming Sphere Models with a Micropillar and Microwell Chip Platform” in SLAS Discovery journal. Ksilink is using such technology and […]

Read More
13
Mar

Come Together Cardiovascular Disease

Posted by | No Tags | news | Comments Off on Come Together Cardiovascular Disease

Ksilink organizes a come together in the field of patient based disease modeling for cardiovascular diseases. Prof Zimmermann from University of Göttingen and Dr. Kirchmeir present the spin off myriamed GmbH, a specialist for standardized engineering of cardiac tissue. Prof. Agbulut from University of Sorbonne is presenting its expertise for Myofibrillar myopathy. Dr. Sinnecker from Technical […]

Read More
28
Feb

Ksilink increases its computing capacity

Posted by | No Tags | news | Comments Off on Ksilink increases its computing capacity

Ksilink acquires one high performance GPU/TPU cluster from locally-based 2CRSI company to implement deep learning approaches to its drug discovery programs for cardiovascular and muscle diseases. Equipped with 4 NVIDIA Tesla V100 Tensor Core delivers up to 125 TeraFlops, the GPU cluster will accelerate AI, high performance computing (HPC), and graphics. In parallel, Ksilink upgrades Checkout, its C++ based […]

Read More
05
Feb

Press Release – Collaboration with I-Stem on ASD and DM1

Posted by | No Tags | news | Comments Off on Press Release – Collaboration with I-Stem on ASD and DM1

Ksilink initiates 2 new drug discovery programs on Muscular Dystrophy-1 (DM1) and Autism Spectrum Disorders (ASD) with its strategic partner I-Stem. Click here to download the press release.

Read More
06
Dec

Press Release – Collaboration with Anagenesis on DMD

Posted by | No Tags | news | Comments Off on Press Release – Collaboration with Anagenesis on DMD

Together with Anagenesis Biotechnologies, Ksilink reachs first exit point in the field of Duchenne Muscular Disease. A major industrial Venture Fund invests into  Anagenesis with a € 3 M seed funding and subsequently up to € 15 M round A investment within the next 18 months. Click here to download the press release.

Read More
28
Sep

New publication in Nature Genetics

Posted by | No Tags | news | Comments Off on New publication in Nature Genetics

Dr YongJun Kwon, Ksilink’s Head of Early Discovery and Technology Development, publishes a paper entitled “Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy” in Nature Genetics journal. This study using patient-derived cancer cells for real-time drug response prediction showcases the power of such approach for precision oncology. Click here for more information.

Read More
18
Jun

Press Release – Collaboration with LCSB on Parkinson’s disease

Posted by | No Tags | news | Comments Off on Press Release – Collaboration with LCSB on Parkinson’s disease

Ksilink teams up with the Luxembourg Centre for Systems Biomedicine (LCSB) of the University of Luxembourg to develop drugs to treat Parkinson’s disease. Together they will develop novel patient-based cell culture models in which they can automatically and with artificial intelligence (AI) test drug candidates from a large substance library. Click here to download the […]

Read More
25
May

AI in Drug Discovery workshop

Posted by | No Tags | news | Comments Off on AI in Drug Discovery workshop

Ksilink organizes a workshop entitled “AI in Drug Discovery”” at ENS in Paris. During this workshop the merits and challenges of implementing AI methods for drug and target discovery based on patient-derived disease models are discussed with Prof Altschuler and Prof Wu from UCSF, Dr Singh from Board Institute of MIT and Harvard and Dr […]

Read More